Figure:
In vivo treatment of NSG mice with fingolimod accelerates engraftment of human UCB cells. Rate of engraftment estimated using a mixed statistical model (p=0.0066).
In vivo treatment of NSG mice with fingolimod accelerates engraftment of human UCB cells. Rate of engraftment estimated using a mixed statistical model (p=0.0066).
